Selcukbiricik F, Erdamar S, Ozkurt C U, Molinas Mandel N, Demirelli F, Ozguroglu M, Tural D, Buyukunal E, Serdengecti S
University of Istanbul, Cerrahpasa Medical Faculty, Istanbul, Turkey.
J BUON. 2013 Jan-Mar;18(1):116-23.
Unlike cetuximab, there is a paucity of biomarkers for bevacizumab as predictors of outcome in metastatic colorectal cancer (mCRC) patients. Obviously exploring the worth of some potential markers in this setting is warranted. The purpose of this study was to investigate the predictive value of the presence of K-RAS and B-RAF mutations on the outcome of patients with mCRC treated with FOLFIRI and bevacizumab combination therapy.
A total of 172 patients with mCRC were evaluated. K-RAS and B-RAF mutations were analyzed by quantitative PCR. Median progression-free survival (PFS) and overall survival (OS) were compared utilizing chi-square and Mann-Whitney U tests, respectively.
Forty-four percent (N=77) of the patients were found to harbor K-RAS mutations and 6 (7.5%) were positive for B-RAF mutations. In baseline no difference in PFS and OS was observed between the groups with or without K-RAS mutation. No relationship was established between K-RAS and B-RAF mutation status and baseline CEA and CA19-9 tumor markers levels.
K-RAS and B-RAF mutations do not seem to be predictive of treatment outcome as potential biomarkers for bevacizumab therapy in mCRC. However, not only the presence of K-RAS and B-RAF mutations but also the different biological behavior of the various subtypes of mutations should be considered as potential determinants in the final outcome of this disease.
与西妥昔单抗不同，作为转移性结直肠癌（mCRC）患者预后预测指标的贝伐单抗生物标志物较少。显然，有必要在此背景下探索一些潜在标志物的价值。本研究的目的是调查K-RAS和B-RAF突变的存在对接受FOLFIRI和贝伐单抗联合治疗的mCRC患者预后的预测价值。
共评估了172例mCRC患者。通过定量PCR分析K-RAS和B-RAF突变。分别使用卡方检验和曼-惠特尼U检验比较无进展生存期（PFS）和总生存期（OS）的中位数。
发现44%（N = 77）的患者存在K-RAS突变，6例（7.5%）B-RAF突变呈阳性。在基线时，有或无K-RAS突变的组之间在PFS和OS方面未观察到差异。K-RAS和B-RAF突变状态与基线癌胚抗原（CEA）和糖类抗原19-9（CA19-9）肿瘤标志物水平之间未建立相关性。
K-RAS和B-RAF突变似乎不能作为mCRC中贝伐单抗治疗的潜在生物标志物来预测治疗结果。然而，不仅K-RAS和B-RAF突变的存在，而且各种突变亚型的不同生物学行为都应被视为该疾病最终结局的潜在决定因素。
